## <u>Drug Injury Watch: Pancreatic Cancer As A Side Effect Of</u> <u>Diabetes Drugs Bydureon, Byetta, Januvia, And Victoza</u>

Health Canada Currently Conducting Epidemiological Study Of These Incretin-Based Type 2 Diabetes Medications To Assess This Potential Drug Safety Issue

(Posted by Tom Lamb at www.DruglnjuryWatch.com on January 19, 2015)

**SUMMARY**: Among the diabetes medications that fall into the incretin-based therapies class of drugs are:

- Bydureon (exenatide)
- Byetta (exenatide)
- Januvia (sitagliptin)
- Victoza (liraglutide)

We have written previously about the possible link between these diabetes drugs and cancer of the pancreas / pancreatic cancer.

From this article in the October 2014 edition of the Canadian Adverse Reaction Newsletter, "Incretin-based therapies and the risk of pancreatic cancer", we learned that there is an epidemiological study being done by Health Canada to assess the potential association between pancreatic cancer and incretin-based diabetes drugs such as Bydureon, Byetta, Januvia, and Victoza.

[Read this article in full at original source]

Earlier Byetta articles by Tom Lamb on the <u>Drug Injury Watch</u> blog:

Byetta / Januvia / Victoza: Update On Possible Association Between These Newer Diabetes

Drugs And Pancreatic Cancer As A Side Effect

<u>Cancer of The Pancreas: Possible Side Effect For Diabetics Who Use Byetta, Januvia, Or Victoza?</u>

Emerging Drug Safety Issue: Possible Increased Risk Of Pancreatic Cancer With Byetta,
Januvia, And Victoza -- Little Is Known About Long-Term Effects

Byetta And Januvia: More Debate About The Possible Increased Risk Of Pancreatitis, Pancreatic Cancer, And Thyroid Cancer

Attorney <u>Tom Lamb</u> represents people in personal injury and wrongful death cases involving unsafe prescription drugs or medication errors. The above article was posted originally on his blog, **Drug Injury Watch** – with live links and readers' Comments.

<a href="http://www.DrugInjuryWatch.com">http://www.DrugInjuryWatch.com</a>